期刊文献+

脑膜炎球菌多糖疫苗安全性及免疫原性评价 被引量:16

Evaluation on safety and immunogenicity of tetravalent A/C/W_(135)/Y meningococcal polysaccharide vaccine
原文传递
导出
摘要 目的评价A、C、W135和Y群脑膜炎球菌多糖疫苗在2~30岁健康人群中接种的安全性与免疫原性。方法采用随机、双盲和平行对照的设计方法 ,对A、C、W135和Y群脑膜炎球菌多糖疫苗接种人群不良反应发生率、抗体阳转率、平均几何滴度(GMT)进行比较。结果免疫后对照组与试验组总体不良反应发生率分别为11.21%和13.79%,其中全身反应发生率分别为6.06%和5.30%,局部反应发生率分别为6.06%和9.85%;免疫后28d,试验组A、C、W135和Y群抗体阳转率均〉94.00%,A和C群抗体阳转率与对照组比较差异均无统计学意义(均P〉0.05),W135和Y群抗体阳转率与对照组比较差异有统计学意义,试验组高于对照组;免疫后抗体GMT分别为A群=394.81、C群=237.32、W135群=326.00、Y群=226.45,均达到保护性水平。结论 A、C、W135和Y群脑膜炎球菌多糖疫苗在2~30岁健康人群中接种有较好的安全性和免疫原性。 Objective To evaluate the safety and immunogenicity of the tetravalent A/C/W135/Y meningococcal polysaccharide vaccine for subjects at age of 2-30 years.Methods A double-blind,randomized,parallel controlled clinical trial was carried out to evaluate side effect rate,positive seroconversion rate and geomatric mean titer(GMT) of the vaccine.Results The side effect rates of the experimental group and the control group were 13.79% and 11.21%;the systemic side effect rates were 5.30% and 6.06% and the local site effect rates were 9.85% and 6.06%,respectively.Seropositive conversion rates of A/C/W135/Y sterilizing antibody of the experiment group were more than 94.0% with the GMT values of 1:394.81,1:237.32,1:326.00,and 1:226.45,respectively.Seropositive conversion rates and values of GMT of W135 and Y sterilizing antibody between the experimental group and the control group were significantly different.Conclusion The group A/C/W135/Y meningococcal conjugate vaccine has good safety and immunogenicity for health persons between 2 to 30 years old.
出处 《中国公共卫生》 CAS CSCD 北大核心 2010年第12期1534-1536,共3页 Chinese Journal of Public Health
关键词 A、C、W135和Y群脑膜炎球菌多糖疫苗 安全性 免疫原性 A/C/W135/Y meningococcal polysaccharide vaccine safety immunogenicity
  • 相关文献

参考文献9

二级参考文献15

  • 1李军宏,王晓军,梁晓峰.我国流行性脑脊髓膜炎的流行概况及预防控制[J].疾病监测,2005,20(4):169-170. 被引量:71
  • 2[2]Frasch EC,Jonathan,Derrick,et al.Vaccines for the prevention of meningococcal disease[J].Clin Microbio Rev,1989,2(2):133-134.
  • 3[3]Reingold AL,Chrisanna M,Donald J,et al.Age-specific differences in duration of clinical protection with meningococcal polysaccharide A Vaccine[J].Lancet,1985,325(11):114.
  • 4[4]Jay M,Susan S,Victor K,et al.Safety and Immunogenicity of a Serogroups A/C Neisseria meninggitidis Oligosaccharide-Protein Conjugate Vaccine in Young Children[J].JAMA.1996,275(5):1549-1503.
  • 5[5]Gerard,Amadou.Pascal,et al.Safety and immunogenicity of three doses of a neisseria meningitides A+C diphtheria conjugate vaccine in infants from niger[J].Ped Infect Dis J,2000,19(2):144-150.
  • 6Frasch CE,Zollinger WD,Poolman JT.Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes[J].Rev Infect Dis,1985,7(4):504-510.
  • 7Zhu P,Hu X,Xu L.Typing Neisseria meningitidis by analysis of restriction fragment length polymorphisms in the gene encoding the class 1 outer membrane protein:application to assessment of epidemics throughout the last 4 decades in China[J].Clin Microbiol,1995,33(2):458-462.
  • 8Siamak P Y,Paula K,Georgina T,et al.Distribution of Serogroups and Genotypes among Disease-Associated and Carried Isolates of Neisseria meningitidis from the Czech Republic,Greece,and Norway[J].Clin Microbiol,2004,42 (11):5146 -5153.
  • 9Ashton F E,Ryan J A,Borczyk A,et al.Emergence of a virulent clone of Neisseria meningitidis serotype 2a that is associated with meningococcal group C disease in Canada[J].Clin Microbiol,1991,29(11):2489-2493.
  • 10Shao Z,Li W,Ren J,et al.Identification of a new Neisseria meningitidis serogroup C clone from Anhui province China[J].Lancet,2006,367(9508):419-423.

共引文献119

同被引文献116

引证文献16

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部